secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001193125-24-003956
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam appoints William H. Lewis as Chair of Board, succeeds founder Sander Slootweg
--------------------------------------------------------------------------------

- William H. Lewis, CEO of Insmed since 2012, appointed Chair of NewAmsterdam's Board effective Jan 4, 2024.
- He replaces Sander Slootweg (Forbion), Chairman since Company inception.
- Lewis receives annual cash retainer $40k + $30k Chair fee + $20k lead director fee; granted 100k share options.
- Board increased to ten; Lewis serves as temporary non-executive director until next shareholder meeting.
- Lewis appointed to Audit and Compensation Committees; meets Nasdaq independence standards.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000119312524003956/0001193125-24-003956-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000119312524003956/d110563d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-003956

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer